{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:50:22Z","timestamp":1788364222435,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00044-021-02766-x","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T03:29:02Z","timestamp":1627010942000},"page":"207-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phosphoryl prodrugs: characteristics to improve drug development"],"prefix":"10.1007","volume":"31","author":[{"given":"Samuel A.","family":"Kirby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5011-7029","authenticated-orcid":false,"given":"Cynthia S.","family":"Dowd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"2766_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/128_2014_561","volume":"360","author":"AJ Wiemer","year":"2015","unstructured":"Wiemer AJ, Wiemer DF. Prodrugs of phosphonates and phosphates: crossing the membrane barrier. Top Curr Chem. 2015;360:115\u201360.","journal-title":"Top Curr Chem"},{"key":"2766_CR2","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1021\/jm701260b","volume":"51","author":"SJ Hecker","year":"2008","unstructured":"Hecker SJ, Erion MD. Prodrugs of phosphates and phosphonates. J Med Chem. 2008;51:2328\u201345.","journal-title":"J Med Chem"},{"key":"2766_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/182421a0","volume":"182","author":"A Albert","year":"1958","unstructured":"Albert A. Chemical aspects of selective toxicity. Nature. 1958;182:421\u20132.","journal-title":"Nature"},{"key":"2766_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-1-349-10705-6_19","volume-title":"Early phase drug evaluation in man","author":"S Toon","year":"1990","unstructured":"Toon S. The assessment of pharmacokinetics. In: O\u2019Grady J, Linet OI, editors. Early phase drug evaluation in man. London: Macmillan Education UK; 1990. p. 229\u201342."},{"key":"2766_CR5","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.1016\/j.bmcl.2011.09.123","volume":"21","author":"E Uh","year":"2011","unstructured":"Uh E, Jackson ER, San Jose G, Maddox M, Lee RE, Lee RE, et al. Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. Bioorg Med Chem Lett. 2011;21:6973\u20136.","journal-title":"Bioorg Med Chem Lett"},{"key":"2766_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.bmcl.2013.11.067","volume":"24","author":"ER Jackson","year":"2014","unstructured":"Jackson ER, San Jose G, Brothers RC, Edelstein EK, Sheldon Z, Haymond A, et al. The effect of chain length and unsaturation on Mtb Dxr inhibition and antitubercular killing activity of FR900098 analogs. Bioorg Med Chem Lett. 2014;24:649\u201353.","journal-title":"Bioorg Med Chem Lett"},{"key":"2766_CR7","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1021\/acsinfecdis.6b00125","volume":"2","author":"G San Jose","year":"2016","unstructured":"San Jose G, Jackson ER, Haymond A, Johny C, Edwards RL, Wang X, et al. Structure-activity relationships of the MEPicides: N-acyl and O-linked analogs of FR900098 as inhibitors of Dxr from mycobacterium tuberculosis and yersinia pestis. ACS Infect Dis. 2016;2:923\u201335.","journal-title":"ACS Infect Dis"},{"key":"2766_CR8","doi-asserted-by":"publisher","first-page":"8847","DOI":"10.1021\/acs.jmedchem.8b01026","volume":"61","author":"X Wang","year":"2018","unstructured":"Wang X, Edwards RL, Ball H, Johnson C, Haymond A, Girma M, et al. MEPicides: \u03b1,\u03b2-unsaturated fosmidomycin analogues as DXR inhibitors against malaria. J Med Chem. 2018;61:8847\u201358.","journal-title":"J Med Chem"},{"key":"2766_CR9","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4155\/fmc-2018-0591","volume":"11","author":"KM Heidel","year":"2019","unstructured":"Heidel KM, Dowd CS. Phosphonate prodrugs: an overview and recent advances. Future Med Chem. 2019;11:1625\u201343.","journal-title":"Future Med Chem"},{"key":"2766_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.","journal-title":"Sci Rep"},{"key":"2766_CR11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa020681","volume":"348","author":"P Marcellin","year":"2003","unstructured":"Marcellin P, Chang T-T, Lim SG, et al. Adefovir Dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808\u201316.","journal-title":"N Engl J Med"},{"key":"2766_CR12","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.bcp.2004.07.010","volume":"68","author":"AS Ray","year":"2004","unstructured":"Ray AS, Vela JE, Olson L, Fridland A. Effective metabolism and long intracellular half life of the anti-hepatitis B agent Adefovir in hepatic cells. Biochem Pharmacol. 2004;68:1825\u201331.","journal-title":"Biochem Pharmacol"},{"key":"2766_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1128\/AAC.38.2.365","volume":"38","author":"KC Cundy","year":"1994","unstructured":"Cundy KC, Shaw JP, Lee WA. Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl) adenine in cynomolgus monkeys. Antimicrob Agents Chemother. 1994;38:365\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3762\/bjoc.15.77","volume":"15","author":"DJ Jones","year":"2019","unstructured":"Jones DJ, O\u2019Leary EM, O\u2019Sullivan TP. An improved synthesis of Adefovir and related analogues. Beilstein J Org Chem. 2019;15:801\u201310.","journal-title":"Beilstein J Org Chem"},{"key":"2766_CR15","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1021\/jm960289o","volume":"39","author":"S Benzaria","year":"1996","unstructured":"Benzaria S, P\u00e9licano H, Johnson R, Maury G, Imbach J-L, Aubertin A-M, et al. Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. J Med Chem. 1996;39:4958\u201365.","journal-title":"J Med Chem"},{"key":"2766_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1023\/A:1018925723889","volume":"11","author":"KC Cundy","year":"1994","unstructured":"Cundy KC, Fishback JA, Shaw JP, Lee ML, Soike KF, Visor GC, et al. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm Res. 1994;11:839\u201343.","journal-title":"Pharm Res"},{"key":"2766_CR17","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0968-0896(02)00552-7","volume":"11","author":"C Schultz","year":"2003","unstructured":"Schultz C. Prodrugs of biologically active phosphate esters. Bioorg Med Chem. 2003;11:885\u201398.","journal-title":"Bioorg Med Chem"},{"key":"2766_CR18","doi-asserted-by":"publisher","first-page":"232595822091923","DOI":"10.1177\/2325958220919231","volume":"19","author":"C Wassner","year":"2020","unstructured":"Wassner C, Bradley N, Lee Y. A review and clinical understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir alafenamide. J Int Assoc Provid AIDS Care. 2020;19:2325958220919231.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2766_CR19","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1128\/AAC.42.9.2380","volume":"42","author":"SG Deeks","year":"1998","unstructured":"Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF. et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother. 1998;42:2380\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1128\/AAC.42.3.687","volume":"42","author":"KC Cundy","year":"1998","unstructured":"Cundy KC, Sueoka C, Lynch GR, Griffin L, Lee WA, Shaw J-P. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Antimicrob Agents Chemother. 1998;42:687\u201390.","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR21","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1023\/A:1012108719462","volume":"14","author":"JP Shaw","year":"1997","unstructured":"Shaw JP, Sueoko CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res. 1997;14:1824\u20139.","journal-title":"Pharm Res"},{"key":"2766_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","volume":"43","author":"BP Kearney","year":"2004","unstructured":"Kearney BP, Flaherty JF, Shah J. Tenofovir Disoproxil Fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43:595\u2013612.","journal-title":"Clin Pharmacokinet"},{"key":"2766_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/jac\/dkq447","volume":"66","author":"PL Anderson","year":"2011","unstructured":"Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for Tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011;66:240\u201350.","journal-title":"J Antimicrob Chemother"},{"key":"2766_CR24","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.3390\/v2122803","volume":"2","author":"G Andrei","year":"2010","unstructured":"Andrei G, Snoeck R. Cidofovir activity against poxvirus infections. Viruses. 2010;2:2803\u201330.","journal-title":"Viruses"},{"key":"2766_CR25","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1128\/AAC.05983-11","volume":"56","author":"W Painter","year":"2012","unstructured":"Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother. 2012;56:2726\u201334.","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.virol.2003.11.015","volume":"318","author":"RM Buller","year":"2004","unstructured":"Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY. Efficacy of oral active ether lipid analogs of Cidofovir in a lethal mousepox model. Virology. 2004;318:474\u201381.","journal-title":"Virology"},{"key":"2766_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","volume":"59","author":"SL Ciesla","year":"2003","unstructured":"Ciesla SL, Trahan J, Wan WB, Beadle JR, Aldern KA, Painter GR, et al. Esterification of Cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antivir Res. 2003;59:163\u201371.","journal-title":"Antivir Res"},{"key":"2766_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.antiviral.2017.01.009","volume":"143","author":"G Chittick","year":"2017","unstructured":"Chittick G, Morrison M, Brundage T, Nichols WG. Short-term clinical safety profile of brincidofovir: a favorable benefit-risk proposition in the treatment of smallpox. Antivir Res. 2017;143:269\u201377.","journal-title":"Antivir Res"},{"key":"2766_CR29","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/cmdc.201500183","volume":"10","author":"M Cesnek","year":"2015","unstructured":"Cesnek M, Jansa P, \u0160m\u00eddkov\u00e1 M, Mertl\u00edkov\u00e1-Kaiserov\u00e1 H, Drac\u00ednsk\u00fd M, Brust TF, et al. Bisamidate prodrugs of 2-substituted 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA, Adefovir) asselective inhibitors of adenylate cyclase toxin from Bordetella pertussis. ChemMedChem. 2015;10:1351\u201364.","journal-title":"ChemMedChem"},{"key":"2766_CR30","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1128\/AAC.39.11.2401","volume":"39","author":"KC Cundy","year":"1995","unstructured":"Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, et al. Clinical pharmacokinetics of Adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 1995;39:2401\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR31","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1158\/1078-0432.CCR-07-2061","volume":"14","author":"H Reiser","year":"2008","unstructured":"Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, et al. GS-9219\u2014a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-hodgkin\u2019s lymphoma. Clin Cancer Res J Am Assoc Cancer Res. 2008;14:2824\u201332.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"2766_CR32","doi-asserted-by":"publisher","first-page":"7970","DOI":"10.1073\/pnas.0502983102","volume":"102","author":"MD Erion","year":"2005","unstructured":"Erion MD, van Poelje PD, Dang Q, Kasibhatla SR, Potter SC, Reddy MR, et al. MB06322 (CS-917): a potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci USA. 2005;102:7970\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2766_CR33","doi-asserted-by":"publisher","first-page":"15491","DOI":"10.1021\/ja074871l","volume":"129","author":"Q Dang","year":"2007","unstructured":"Dang Q, Kasibhatla SR, Reddy KR, Jiang T, Reddy MR, Potter SC, et al. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes. J Am Chem Soc. 2007;129:15491\u2013502.","journal-title":"J Am Chem Soc"},{"key":"2766_CR34","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/cmdc.200900289","volume":"4","author":"Y Mehellou","year":"2009","unstructured":"Mehellou Y, Balzarini J, McGuigan C. Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells. ChemMedChem. 2009;4:1779\u201391.","journal-title":"ChemMedChem"},{"key":"2766_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrd4010","volume":"12","author":"LP Jordheim","year":"2013","unstructured":"Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013;12:447\u201364.","journal-title":"Nat Rev Drug Discov"},{"key":"2766_CR36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"E De Clercq","year":"2016","unstructured":"De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29:695\u201347.","journal-title":"Clin Microbiol Rev"},{"key":"2766_CR37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","volume":"63","author":"PJ Ruane","year":"2013","unstructured":"Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, et al. Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of Tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr 1999. 2013;63:449\u201355.","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"2766_CR38","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1128\/AAC.00128-15","volume":"59","author":"E Murakami","year":"2015","unstructured":"Murakami E, Wang T, Park Y, Hao J, Lepist E-I, Babusis D, et al. Implications of efficient hepatic delivery by Tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother. 2015;59:3563\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR39","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1128\/AAC.01834-15","volume":"60","author":"G Birkus","year":"2015","unstructured":"Birkus G, Bam RA, Willkom M, Frey CR, Tsai L, Stray KM, et al. Intracellular activation of Tenofovir alafenamide and the effect of viral and host protease inhibitors. Antimicrob Agents Chemother. 2015;60:316\u201322.","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR40","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40265-014-0247-z","volume":"74","author":"GM Keating","year":"2014","unstructured":"Keating GM. Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs. 2014;74:1127\u201346.","journal-title":"Drugs"},{"key":"2766_CR41","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1128\/AAC.00193-07","volume":"51","author":"G Asif","year":"2007","unstructured":"Asif G, Hurwitz SJ, Shi J, Hernandez-Santiago BI, Schinazi RF. Pharmacokinetics of the antiviral agent beta-D-2\u2019-deoxy-2\u2019-fluoro-2\u2019-C-methylcytidine in rhesus monkeys. Antimicrob Agents Chemother. 2007;51:2877\u201382.","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR42","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.dmpk.2020.04.333","volume":"35","author":"T Wang","year":"2020","unstructured":"Wang T, Babusis D, Park Y, Niu C, Kim C, Zhao X. et al. Species differences in liver accumulation and metabolism of nucleotide prodrug sofosbuvir. Drug Metab Pharmacokinet. 2020;35:334\u201340.","journal-title":"Drug Metab Pharmacokinet"},{"key":"2766_CR43","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1128\/AAC.01262-12","volume":"57","author":"J Denning","year":"2013","unstructured":"Denning J, Cornpropst M, Flach SD, Berrey MM, Symonds WT. Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects. Antimicrob Agents Chemother. 2013;57:1201\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR44","unstructured":"National Cancer Institute. FDA approval for gemcitabine hydrochloride. National Cancer Institute. 2017. https:\/\/web.archive.org\/web\/20170405134518\/https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/fda-gemcitabine-hydrochloride. Accessed 25 Feb 2021."},{"key":"2766_CR45","doi-asserted-by":"publisher","first-page":"3477.","DOI":"10.1158\/1078-0432.CCR-07-4521","volume":"14","author":"SA Veltkamp","year":"2008","unstructured":"Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H. et al. Oral administration of gemcitabine in patients with refractory tumors: a Clinical and Pharmacologic Study. Clin Cancer Res. 2008;14:3477.","journal-title":"Clin Cancer Res"},{"key":"2766_CR46","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1200\/JCO.2004.10.142","volume":"22","author":"JM Reid","year":"2004","unstructured":"Reid JM, Qu W, Safgren SL, Ames MM, Krailo MD, Seibel NL, et al. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:2445\u201351.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2766_CR47","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/s41416-018-0244-1","volume":"119","author":"SP Blagden","year":"2018","unstructured":"Blagden SP, Rizzuto I, Suppiah P, O\u2019Shea D, Patel M, Spiers L, et al. Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study. Br J Cancer. 2018;119:815\u201322.","journal-title":"Br J Cancer"},{"key":"2766_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1128\/AAC.40.1.22","volume":"40","author":"L Naesens","year":"1996","unstructured":"Naesens L, Balzarini J, Bischofberger N, De Clercq E. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother. 1996;40:22\u201328.","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/095632029700800610","volume":"8","author":"M Arimilli","year":"1997","unstructured":"Arimilli M, Kim C, Dougherty J, Mulato A, Oliyai R, Shaw J, et al. Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs. Antivir Chem Chemother. 1997;8:557\u201364.","journal-title":"Antivir Chem Chemother"},{"key":"2766_CR50","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1128\/AAC.42.7.1568","volume":"42","author":"L Naesens","year":"1998","unstructured":"Naesens L, Bischofberger N, Augustijns P, Annaert P, Van den Mooter G, Arimilli MN, et al. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother. 1998;42:1568\u201373.","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR51","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1021\/mp900036s","volume":"6","author":"L Durand-Gasselin","year":"2009","unstructured":"Durand-Gasselin L, Van Rompay KKA, Vela JE, Henne IN, Lee WA, Rhodes GR, et al. Nucleotide analogue prodrug Tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol Pharm. 2009;6:1145\u201351.","journal-title":"Mol Pharm"},{"key":"2766_CR52","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","volume":"36","author":"KC Cundy","year":"1999","unstructured":"Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues Cidofovir and Adefovir. Clin Pharmacokinet. 1999;36:127\u201343.","journal-title":"Clin Pharmacokinet"},{"key":"2766_CR53","doi-asserted-by":"publisher","unstructured":"Eriksson U, Peterson LW, Kashemirov BA, Hilfinger JM, Drach JC, Borysko KZ, et al. Serine peptide phosphoester prodrugs of cyclic Cidofovir: synthesis, transport, and antiviral activity. Mol Pharm. https:\/\/doi.org\/10.1021\/mp8000099. Accessed 19 Jan 2021.","DOI":"10.1021\/mp8000099"},{"key":"2766_CR54","doi-asserted-by":"crossref","unstructured":"Baggot JD. Pharmacokinetic terms: symbols and units. J Vet Pharmacol Ther. 2001. https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2885.2001.00340.x. Accessed 11 Jun 2021.","DOI":"10.1046\/j.1365-2885.2001.00340.x"},{"key":"2766_CR55","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1158\/1078-0432.CCR-08-3113","volume":"15","author":"DM Vail","year":"2009","unstructured":"Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GHI, Watkins WJ, et al. Assessment of GS-9219 in a pet dog model of non-Hodgkin\u2019s lymphoma. Clin Cancer Res J Am Assoc Cancer Res. 2009;15:3503\u201310.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"2766_CR56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1021\/mp3002045","volume":"10","author":"D Babusis","year":"2013","unstructured":"Babusis D, Phan TK, Lee WA, Watkins WJ, Ray AS. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm. 2013;10:459\u201366.","journal-title":"Mol Pharm"},{"key":"2766_CR57","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","volume":"49","author":"WA Lee","year":"2005","unstructured":"Lee WA, He G-X, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor Tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49:1898\u2013906.","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR58","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","volume":"54","author":"BJ Kirby","year":"2015","unstructured":"Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54:677\u201390.","journal-title":"Clin Pharmacokinet"},{"key":"2766_CR59","unstructured":"Babusis D, Curry MP, Denning J, Wang T, Kirby B, Murakami E, et al. Translational studies to understand the mechanism of liver delivery by sofosbuvir [oral presentation]. 2014."},{"key":"2766_CR60","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jconrel.2004.09.001","volume":"100","author":"ML Immordino","year":"2004","unstructured":"Immordino ML, Brusa P, Rocco F, Arpicco S, Ceruti M, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release J Control Release Soc. 2004;100:331\u201346.","journal-title":"J Control Release J Control Release Soc"},{"key":"2766_CR61","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1021\/jm401853a","volume":"57","author":"M Slusarczyk","year":"2014","unstructured":"Slusarczyk M, Lopez MH, Balzarini J, Mason M, Jiang WG, Blagden S, et al. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J Med Chem. 2014;57:1531\u201342.","journal-title":"J Med Chem"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-021-02766-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-021-02766-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-021-02766-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T07:21:29Z","timestamp":1675581689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-021-02766-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2766"],"URL":"https:\/\/doi.org\/10.1007\/s00044-021-02766-x","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}